Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Rctrader2 who wrote (93846)	10/16/2001 1:45:52 PM
From: Rocket Red	Read Replies (1) \| Respond to of 150070

ARCC Whaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaat

To: Rctrader2 who wrote (93846)	10/16/2001 2:26:28 PM
From: Jim Bishop	Respond to of 150070

DISE Disease Sciences, Inc. Ultra-High Pressure Pulse Technology Kills Conventional Pathogens Including Anthrax Ultra-High Pressure Pulse Technology May be Used to Kill Anthrax in Food, Water and Eventually Mail and Packages Boca Raton, Fla., Oct 16, 2001 (BUSINESS WIRE) -- Disease Sciences, Inc. (OTC BB: DISE) announced today that the Company's research study using ultra-high pressure pulses to clean the meat and plasma supply of Scrapie infectivity, the agent believed to cause Transmissible Spongiform Encephalopathy ("TSE"), has been shown to disinfect all conventional pathogens, including highly resistant bacterial spores. Dr. Paul Brown, Research Study Principal Investigator and Disease Sciences Scientific Advisory Committee member, stated, "we hope this technology may be capable of reducing or eliminating the infectivity associated with the protein thought to be responsible for causing Transmissible Spongiform Encephalopathies (TSE's). Resistant to temperatures of up to 400 degrees Celsius, these rogue proteins are very resilient and much harder to destroy than Conventional Pathogens used in Bio-terrorism. This technology has already been shown to kill several bacterial spore species, and it is highly probable that it could kill spores of the Anthrax Bacillus. "With the recent Anthrax scares in our own backyard and the threat of Biological terrorism throughout the United States and abroad, we would be proud to use these technologies to universally fight terrorism. With the help of Dr. Brown we may be able to develop a simple, inexpensive method for cleaning our food and water supplies should they come under attack from bio-terrorism, as well as sterilize other items such as mail and packages that could be accommodated in the pressure apparatus. Ultra-pulse high-pressure pulse technology is unique in that there is no irradiation, microwave, pasteurization or other chemical components used in this process that are harmful to humans. "Stated Dr. Wayne Goldstein CEO. About Disease Sciences Inc. Disease Sciences, Inc. is a developmental stage biopharmaceutical/clinical diagnostics Company planning to employ a broad array of technologies to detect, identify and quantify substances in blood or other bodily fluids and tissues. It's primary goal will be a Transmissible Spongiform Encephalopathy ("TSE") test, useful in the diagnosis of TSE diseases such as Bovine Spongiform Encephalopathy ("BSE") in cattle, (commonly known as "mad-cow disease"), Scrapie in sheep, Chronic Wasting Disease ("CWD") in wild deer and elk and Creutzfeldt-Jakob Disease ("CJD") in humans. Test results are to be used in the diagnosis, detection, evaluation, monitoring and potential treatment of diseases and other medical conditions. The Company intends to derive its revenues from patent sub-licensing fees, royalties from pharmaceutical sales, appropriate milestone payments and research and development contracts. The Company, maintains a website at www.diseasesciences.com. Safe Harbor Act Disclaimer: This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including, without limitation, successful implementation of the Company's business strategy and competition, any of which may cause actual results to differ materially from those described in the statements. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission. CONTACT: Investor Awareness, Inc. Tony Schor/Paul Arndt, 847-945-2222 URL: www.investorawareness.com or Disease Sciences, Inc. Dr. Wayne Goldstein, 561/487-3655 www.diseasesciences.com businesswire.com Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. Copyright (C) 2001 Business Wire. All rights reserved. -0- KEYWORD: ILLINOIS FLORIDA INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL PHARMACEUTICAL MARKETING AGREEMENTS SOURCE: Disease Sciences, Inc. * end of story *